RA0316

antibody from Oursmab

Targeting: IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0316

Provider

Oursmab

Product name

Cixutumumab (Biosimilar Reference Antibody) (IGF1R)

Antibody type

Monoclonal

Description

Cixutumumab (also known as IMC-A12) is an investigational fully human monoclonal antibody that was developed as a targeted therapy for cancer. It functions by inhibiting the activity of a key receptor involved in cell growth, proliferation, and survival. Clinical trials evaluated its efficacy, both as a monotherapy and in combination with other agents (such as chemotherapy or targeted therapies), for a range of solid tumors, including sarcomas, prostate cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). Despite promising preclinical data, its clinical development was ultimately discontinued as later-phase trials did not demonstrate sufficient improvement in overall survival to support regulatory approval.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.